Author

Chiara Adele Cavarretta

Observed names: C. A. Cavarretta, C.A. Cavarretta, Chiara Adele Cavaretta, Chiara Cavaretta

Institution: University of Padua

Observed institutions: University of Padua, Azienda Ospedale - Università Padova

ORCID: 0000-0002-5757-5687

Observed ORCID: 0000-0002-5757-5687

OpenAlex ID: A5005223256

From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance

2022 · Andrea Visentin, Stefano Pravato, et al. · Cancers · 21

PDF

A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency

2022 · Andrea Visentin, Maria Chiara Molinari, et al. · Current Oncology · 17

PDF

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies

2023 · Francesco Angotzi, Marco Petrella, et al. · Frontiers in Oncology · 9

Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy

2024 · Edoardo Ruggeri, Federica Frezzato, et al. · Frontiers in Immunology · 7

Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax‐based regimens

2024 · Andrea Serafin, Alessandro Cellini, et al. · British Journal of Haematology · 7

PDF

Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course

2024 · Francesco Angotzi, Alessandro Cellini, et al. · Cancers · 6

PDF

Continuous venetoclax in treatment‐naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study

2023 · Andrea Visentin, Francesca Romana Mauro, et al. · American Journal of Hematology · 4

PDF

Serum soluble interleukin‐2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring

2025 · Francesco Angotzi, Alessandro Cellini, et al. · British Journal of Haematology · 3

PDF

Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD

2024 · Alessandro Cellini, Chiara Adele Cavarretta, et al. · Frontiers in Oncology · 3

PDF

P27 High Dose Cyclophosphamide as Mobilization Regimen in Newly Diagnosed Multiple Myeloma: Safety and Efficacy in an Outpatient Setting. Single Center Experience

2023 · L. Massarotti, A. Branca, et al. · HemaSphere · 3

P1075: Advanced-stage Chl International Prognostication Index: External Validation in a Single-center Retrospective Patient Dataset and Comparison to the Hasenclever Ips

2023 · Alessandro Cellini, Chiara Adele Cavarretta, et al. · HemaSphere · 2

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

2023 · Andrea Visentin, Enrico Gaffo, et al. · Blood · 1

Serum Soluble Interleukin-2 Receptor Levels in Hairy Cell Leukemia As a Marker of Tumor Burden with Prognostic Value and As a Tool for Disease Monitoring

2023 · Francesco Angotzi, Simone Zoletto, et al. · Blood · 1

PDF

P680: Sarcopenia Evaluated by Ct Scan Is Associated With Shorter Survival in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Therapies. a Prospective Study.

2022 · A. Visentin, F. Crimì, et al. · HemaSphere · 1

P1076: a Retrospective Analysis on Old and Emerging Prognostic Factors in Classical Hodgkin’s Lymphoma in the Pet-guided Era

2022 · A. Cellini, C. A. Cavarretta, et al. · HemaSphere · 1

Anaemia during venetoclax ramp‐up phase: Do not forget unusual causes

2022 · Chiara Adele Cavarretta, Andrea Visentin, et al. · International Journal of Laboratory Hematology · 1

Prognostic and predictive impact of NOTCH1 mutations in patients with chronic lymphocytic leukemia: a tertiary single-center experience

2026 · Mattia D’Antiga, Andrea Serafin, et al. · Frontiers in Oncology

PDF

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma

2022 · Andrea Visentin, Edoardo Ruggeri, et al. · HemaSphere

P005: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.

2022 · Andrea Visentin, Alessandro Cellini, et al. · HemaSphere

Works count: 23

Citation count: 87

H-index: 6

I10-index: 2